US09074F2074 - Common Stock
BIOVIE INC
NASDAQ:BIVI (9/6/2024, 8:02:13 PM)
2.49
-0.14 (-5.32%)
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company is headquartered in Carson City, Nevada and currently employs 18 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The firm is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
BIOVIE INC
680 W Nye Lane, Suite 201
Carson City NEVADA 90404
P: 17758883162
CEO: Cuong Do
Employees: 18
Website: https://www.bioviepharma.com/
Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim’s impact on neurological symptoms...
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Bezisterim appears to possess broad homeostatic properties relevant to inflammation and human disorders related to aging Patients treated with bezisterim...
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to...
Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024...
Here you can normally see the latest stock twits on BIVI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: